Concert Pharmaceuticals (NASDAQ: [[ticker:CNCE]]) has appointed Jeffrey Munsie to serve as its chief legal officer. Munsie was most recently senior vice president, general counsel, and head of corporate operations at Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]). Earlier this month, Lexington, MA-based Concert released positive Phase 2 data for CTP-543, an experimental treatment for hair loss caused by alopecia areata.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
